Findings on Cancer Gene Therapy Discussed by Investigators at University of Alabama (Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news reporting out of Birmingham, Alabama, by NewsRx editors, research stated, "Pancreatic cancer is a significant clinical problem and novel therapeutic approaches are desperately needed. Recent advances in conditionally replicative adenovirus-based (CRAd) oncolytic virus design allow the application of CRAd vectors as a therapeutic strategy to efficiently target and eradicate chemoresistant pancreatic cancer cells, thereby improving the efficacy of pancreatic cancer treatment."
Our news journalists obtained a quote from the research from the University of Alabama, "The goal of this study was to construct and validate the efficacy of an infectivity-enhanced, liver-untargeted, tumor-specific CRAd vector. A panel of CRAds has been derived that embodies the C-X-C chemokine receptor type 4 promoter for conditional replication, two-fiber complex mosaicism for targeting expansion and hexon hypervariable region 7 (HVR7) modification for liver untargeting. We evaluated CRAds for cancer virotherapy using a human pancreatic tumor xenograft model. Employment of the fiber mosaic approach improved CRAd replication in pancreatic tumor xenografts. Substitution of the HVR7 of the Ad5 hexon for Ad serotype 3 hexon resulted in decreased liver tropism of systemically administrated CRAd."
According to the news editors, the research concluded: "Obtained data demonstrated that employment of complex mosaicism increased efficacy of the combination of oncolytic virotherapy with chemotherapy in a human pancreatic tumor xenograft model."
For more information on this research see: Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus. Cancer Gene Therapy, 2014;21(7):264-274. Cancer Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Cancer Gene Therapy - www.nature.com/cgt/)
Our news journalists report that additional information may be obtained by contacting S.A. Kaliberov, Univ Alabama Birmingham, Dept. of Radiat Oncol, Div Radiat Biol, Birmingham, AL, United States. Additional authors for this research include L.N. Kaliberova, D.J. Buchsbaum and D.T. Curiel (see also Biotechnology).
Keywords for this news article include: Biotechnology, Alabama, Oncology, Carcinoma, Xenograft, Birmingham, Adenovirus, United States, Gastroenterology, Pancreatic Cancer, Xenotransplantion, Cancer Gene Therapy, Pancreatic Neoplasms, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC